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Abstract 
Background: CD133 is a marker of stem cells as well cancer stem cells. This study investigated the association 
between CD133 expression in cancer cells and the clinical outcome of non-mucin producing intrahepatic cholangio-
carcinoma (ICC).
Methods: Fifty-seven non-mucin producing ICC patients were enrolled in this study. Immunohistochemistry (IHC) 
and immunofluorescence staining for CD133 as well as other cancer-associated proteins, including cytokeratin 19, 
TGF-β1, p-Smad2 and epithelial–mesenchymal transition (EMT) markers S100A4, E-Cadherin and Vimentin were 
analyzed.
Results: IHC staining showed that tumor cells in 52.6% of patients expressed CD133. The  CD133+ patients had 
significantly higher metastasis rate than those without  CD133+ tumor cells (36.7% vs. 10.1%, p = 0.03). The  CD133+ 
patients had shorter overall and disease-free survival time as compared to the  CD133− patients. Furthermore, 90.9% 
of  CD133+ patients developed cancer recurrence, as compared to 64.3% of  CD133− patients (p = 0.02). As compared 
to  CD133− patients, tumor cells in  CD133+ patients demonstrated high levels of TGF-β/p-Smad2 as well as EMT-like 
alteration, characterized by loss of E-Cadherin and expression of Vimentin and S100A4.
Conclusions: CD133 expression in ICC tumor cells indicates poor prognosis of the disease and might be associated 
with TGF-β related EMT alterations.
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Background
Cholangiocarcinoma (CCA) is the second most com-
mon hepatic malignancy after hepatocellular carcinoma 
(HCC) and has a very poor prognosis with the 5-year 
survival rate <  10% [1]. In terms of the location of the 
malignancy, CCA can be mainly divided into extra-
hepatic cholangiocarcinoma (ECC) and intrahepatic 
cholangiocarcinoma (ICC). In addition, ICC can also be 
categorized into mucin-producing and mucin-negative. 
The former arises from large bile duct cells and the latter 
from small bile duct cells or liver progenitor cells (LPC) 
[2, 3].
CD133 is a five-transmembrane cell-surface glycopro-
tein and a marker of stem cells or progenitor cells [4]. It 
has been used for the identification of cancer stem cells 
(CSCs) in several types of cancers including CCA [5–7]. 
CD133 expression is related to poor prognosis of colon 
cancer and HCC [8, 9]. Two studies showed that CD133 
positive CCA had poor prognosis, while another study 
demonstrated the opposite result [10–12]. How CD133 
impacts progression of CCA remains unknown.
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Mucing-producing ICC and non-mucin producing 
ICC exhibit variable biological and clinicopathological 
features as well as different outcomes. Generally, non-
mucin producing ICC is similar to cancer stem cells due 
to its possible origin from LPC. In this study, we enrolled 
patients with non-mucin producing and investigated 
the correlation between CD133 expression and disease 
prognosis.
Methods
Patients and specimens
A total of 59 non-mucin producing ICC patients con-
firmed by pathologically HE staining who received cura-
tive surgery from January 2004 to December 2014 (33 
from Shanghai General Hospital, Shanghai Jiaotong Uni-
versity School of Medicine, Shanghai, China and 26 from 
University Medical Center Hamburg-Eppendorf, Ham-
burg, Germany) were enrolled. Two patients lost during 
the follow-up. Hence, 57 patients, 39 men and 18 women, 
were eventually included in the study. The mean follow-
up duration was 25.7  ±  19.1  months. The tumor stage 
was determined according to the 2009 UICC TNM clas-
sification system [13].
The clinical study was approved by the Ethics Commit-
tee of Shanghai General Hospital, Shanghai Jiaotong Uni-
versity School of Medicine and the ethics committee of 
Medical Association of Hamburg. Informed consent was 
obtained from all participants.
Histology
Liver tissues were fixed in 4% formaldehyde and embed-
ded in paraffin. 4  μm sections was used for hematoxy-
lin–eosin, Sirius red and immunohistochemistry (IHC) 
staining. The inflammation grades and fibrosis stages of 
the peri-tumoral tissues were examined by two experi-
enced pathologists according to the Scheuer scoring sys-
tem [14].
For IHC, the sections were boiled in 10  mM sodium 
citrate buffer (pH 6.0) for 10  min for antigen unmask-
ing. After cooling, the sections were incubated in peroxi-
dase blocking reagent (Dako) for 1 h and then incubated 
with the following primary antibodies at 4  °C for over-
night: anti-CK19 (Dako, Hamburg, Germany), 1:200; 
anti-CD133 (R&D Biotechnology, USA), 1:200; anti-
TGF-β1 (Santa Cruz Biotechnology, USA), 1:200; anti-
p-Smad2 (Santa Cruz Biotechnology, USA), 1:100; and 
anti-S100A4 (Sigma-Aldrich Biotechnology, Germany), 
1:200; anti-E-Cadherin (1:200; Abcam) and anti-Vimen-
tin (1:200; Abcam). Next day, the sections were incubated 
at room temperature with the secondary antibody and 
developed with diaminobenzidine for 5 min.
For semiquantitative analysis, IHC scores were cal-
culated as follows: grade 0, <  1% positive cells; grade 1, 
≥ 1% and < 25% positive cells; grade 2, ≥ 25% and < 50% 
positive cells; grade 3, ≥ 50% and < 75% positive cells; and 
grade 4, ≥ 75% positive cells. Since p-Smad2 is commonly 
expressed in tumor cells, we also evaluated the inten-
sity of p-Smad2 staining: grades 1–4: (1) weak positive 
staining: yellow; (2) moderate positive staining: brown; 
(3) strong positive staining: deep brown; (4) very strong: 
black. The final immune staining score for p-Smad2 was 
calculated as positive area * staining intensity.
For double-fluorescence immunostaining for E-Cad-
herin and Vimentin, the slides were washed with PBS 
and incubated with anti-E-Cadherin antibody (1:100; 
Abcam) at 4 °C overnight. Then, the slides were washed 
with PBS and incubated with anti-Vimentin antibody 
(1:100; Abcam) at 4  °C overnight. Next, the slides were 
incubated with secondary antibodies, Alexa 633 IgG and 
Alexa 488 IgG (Molecular Probes/Invitrogen, Karlsruhe, 
Germany) for 30 min at room temperature. The samples 
were mounted using Dako-Cytomation Fluorescence 
Mounting Medium. The slides were imaged with a confo-
cal microscope (Leica, Heidelberg, Germany).
Statistical analysis
Data were analyzed using the SPSS version 13.0 for Win-
dows (SPSS Inc, Chicago, IL, USA), and are presented as 
means and standard deviations (±  SD). Student’s t-test 
was used to compare the continuous quantitative data. A 
two-tailed Wilcoxon signed rank test was used to com-
pare ranked variables. The Kaplan–Meier analysis was 
applied to evaluate overall and disease-free survival, and 
different groups were compared with the log-rank test. 
p < 0.05 was considered to be statistically significant.
Results
CD133 expression in ICC
IHC staining showed that 30 patients (52.6%) had CD133 
expression on the membrane of tumor cells. Besides 
cancer cells, CD133 was also expressed in peri-tumoral 
ductular reaction (DR). Interestingly, hepatocytes in two 
patients also expressed CD133 (Fig.  1a). Furthermore, 
we analyzed the relationship between CD133 expres-
sion and liver inflammation and fibrosis.  CD133+ ICC 
displayed more severe liver inflammation and fibrosis in 
peri-tumoral areas than  CD133− ICC, although the dif-
ference was not statistically significant (p  =  0.056 and 
0.06, respectively, Fig. 1b).
ICC patients with CD133 expression had poor prognosis
Next, we analyzed clinical outcome of ICC patients 
according to CD133 expression in tumor cells. The 
 CD133+ patients had significantly higher metastasis rate 
than  CD133− patients at the time of diagnosis (36.7% 
vs. 10.1%, p =  0.03). We followed up these patients for 
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25.7  ±  19.1  months and found that 90.9% of  CD133+ 
patients had ICC recurrence, as compared to 64.3% of 
 CD133− patients(p  =  0.02, Table  1). Survival analysis 
showed shorter overall and disease-free survival rates 
in  CD133+ patients as compared to  CD133− patients 
(Fig.  2). These results suggested that CD133 expression 
was related to poor prognosis in non-mucin producing 
ICC patients.
CD133+ cancer cells demonstrated EMT markers
Given that tumor metastasis is closely associated with 
EMT, we performed IHC staining for S100A4, a marker 
of EMT, in liver tissue samples.  CD133+ patients had 
higher levels of S100A4 in tumor cells than  CD133− 
patients (2.10 ± 0.21 vs. 1.12 ± 0.20, p = 0.001). S100A4 
protein was localized in the cytoplasm, nucleus, or both. 
More patients had nuclear expression of S100A4 in the 
 CD133+ group, although without statistical significance 
(65% vs. 40%, p = 0.193 Fig. 3a, b).
To further verify the relationship between EMT and 
CD133 expression, we performed fluorescence co-
immunostaining for E-Cadherin, an epithelial marker, 
and Vimentin, a mesenchymal marker, in CD133 posi-
tive and negative patients, respectively. As compared to 
 CD133− tumor cells,  CD133+ ICC lost epithelial marker 
E-Cadherin and acquired mesenchymal marker Vimen-
tin, indicating an EMT-like alteration in these tumor cells 
(Fig. 3c). IHC staining showed the trend of higher expres-
sion of E- cadherin and lower expression of Vimentin 
in  CD133− ICC than in  CD133+ patients(p =  0.18 and 
p = 0.06, respectively) (Fig. 3d).
Given a crucial role of TGF-β1 in EMT, we investi-
gated the expression of TGF-β1 and its downstream 
protein p-Smad2 by IHC. Expression of TGF-β1 in 
tumor cells was seen in most ICC patients (Fig.  4a). 
However,  CD133+ patients displayed higher levels of 
TGF-β1 expression in tumor cells than  CD133− patients 
(p  =  0.017, Fig.  4b). Consistent with high levels of 
Fig. 1 CD133 expression in tumor and peri-tumoral tissues. a CD133 expressed in tumor cells, peri-tumoral hepatocytes and ductular cells. b The 
relationship between CD133 expression in tumor and peri-tumoral liver inflammation and fibrosis
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TGF-β1,  CD133+ tumor cells also expressed higher levels 
of p-Smad2 than  CD133− tumor cells (p = 0.008, Fig. 4c, 
d).
Discussion
Several clinical studies had investigated the relation-
ship between CD133 expression and clinical outcome 
of cholangiocarcinoma (Ref.). However, the results are 
controversial. Shimada and colleagues showed that 
CD133 expression in tumor cells was an indicator of poor 
prognosis for ICC patients. The 5-year survival rate was 
lower in  CD133+ patients than in  CD133− patients (8% 
vs. 57%) [10]. Another study with 34 ICC and perihilar 
CC patients also demonstrated that strong expression 
of CD133 in tumor was related to nodal metastasis and 
positive surgical margin status. Furthermore,  CD133+ 
cells had a higher invasive ability in vitro [11]. However, 
Fan et al. study with 25 ICC and 29 perihilar CC patients 
displayed opposite result [12], wherein positive expres-
sion of CD133 in tumor cells was correlated with high 
or moderate tumor differentiation and predicted better 
prognosis of the disease. Notably, these studies included 
different subtypes of CCA and did not focus on ICC. ICC 
is divided into two groups according to the presence or 
absence of mucin products [2]. The mucin-producing 
ICC arises from large bile duct epithelial cells similar to 
perihilar or extrahepatic CC, while the non-mucin pro-
ducing ICC arises from small bile ducts or LPC. A study 
with 87 cases of ICC demonstrated that ICC from large 
ducts had significantly higher incidence of perineu-
ral invasion, lymph node metastasis, vascular invasion, 
intrahepatic metastasis and recurrence as well as worse 
survival as compared to ICC from small ducts [15]. 
Therefore, the role of CD133 in different pathological 
types of CCA might be different.
The current study focused on the relationship between 
CD133 expression and non-mucin producing ICC. We 
found that more than 50% of non-mucin producing ICC 
patients expressed CD133 in tumor cells. These  CD133+ 
patients had higher metastasis and recurrence rate after 
surgery and worse overall and disease-free survival. 
These results suggested that CD133 is an indicator for 
poor prognosis of non-mucin producing ICC.
Table 1 Comparison of  clinicopathological parameters 
between  CD133− and  CD133+ ICC patients
CD133− (n = 27) CD133+ (n = 30) P
Age 57.4 ± 8.4 60.5 ± 11.5 0.47
Gender 0.76
 Male 19 (70.3%) 20 (66.7%)
 Female 8 (29.7%) 10 (33.3%)
TNM stages
 T 0.37
  1–2 14 (51.9%) 12 (40.0%)
  3–4 13 (48.1%) 18 (60.0%)
 N 0.41
  0 19 (70.4%) 18 (60.0%)
  1 8 (29.6%) 12 (40.0%)
 M 0.03
  0 24 (88.9%) 19 (63.3%)
  1 3 (10.1%) 11 (36.7%)
Differentiation 0.89
 1–2 14 (51.9%) 15 (50.0%)
 3–4 13 (48.1%) 15 (50.0%)
Recurrence 0.02
 0 10 (35.7%) 3 (10.0%)
 1 18 (64.3%) 27 (90.9%)
Fig. 2 Survival analysis showed that overall and disease-free survival (DFS) were higher in the CD133 negative group than in the CD133 positive 
group
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CD133 is thought to be a marker of CSC also known 
as tumor-initiating cells, which are responsible for 
metastasis, chemotherapy resistance, and tumor recur-
rence [16]. CSC exhibit EMT phenotype that facilitate 
tumor metastasis and recurrence. Thus, we investigated 
the relationship between CD133 expression and tumor 
EMT. We examined the expression of an EMT marker 
S100A4 in ICC tissue samples.  CD133+ patients had 
higher total S100A4 and nuclear S100A4 expression. 
Fabris et  al. showed that nuclear expression of S100A4 
by CCA tumor cells was a strong predictor of metastasis 
and poor survival after resection by increasing CCA cell 
motility, invasiveness, and MMP-9 secretion [17]. These 
findings partially explain why  CD133+ ICC patients have 
poor prognosis. Next, we performed immunostaining for 
epithelial marker E-Cadherin and mesenchymal marker 
Vimentin and found that  CD133+ ICC cells underwent 
EMT-like alteration characterized by lower E-Cadherin 
and higher Vimentin expression, indicating that EMT 
might be a mechanism linking CD133 expression with 
poor prognosis.
TGF-β1 is a key cytokine for inducing EMT, which 
contributes to tumor metastasis and recurrence [18]. 
Therefore, we evaluated the relationship between CD133 
expression and activation of TGF-β1 signaling in ICC. As 
expected,  CD133+ ICC displayed both higher levels of 
TGF-β1 and p-Smad2 expression. These results suggested 
a potential link between enhanced TGF-β1–Smad2 sign-
aling and CD133 expression in non-mucin producing 
ICC.
Our study demonstrated that CD133 expression in 
tumor cells is an indicator for poor prognosis of non-
mucin producing ICC. CD133 expression in tumor cells 
might be associated with TGF-β1-p-Smad2-EMT axis in 
Fig. 3 CD133+ tumor cells showed EMT phenotype. a S100A4 expression in tumor cells. b Expression of total S100A4 and nuclear S100A4 was 
higher in the tumors of  CD133+ patients than in  CD133− patients. c A representative patient with CD133 positive expression showed loss of 
E-Cadherin and expression of Vimentin as well as altered cell shape. d IHC staining showed the trend of higher expression of Vimentin and less 
expression of E-Cadherin in  CD133+ patients than  CD133− patients
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ICC. The underlying detailed mechanisms require fur-
ther investigation in the future.
Conclusions
Our current work is the first attempt to evaluate the 
role of CD133 expression in tumor cells for the progno-
sis of non-mucin producing ICC, providing additional 
insights on the molecular events responsible for prog-
nosis prediction and antitumor potency.
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